Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TJ7R
|
|||
| Former ID |
DNC007496
|
|||
| Drug Name |
1-benzyl-4-phenylpiperidin-4-ol
|
|||
| Synonyms |
1-Benzyl-4-phenylpiperidin-4-ol; 63843-83-4; 1-Benzyl-4-phenyl-4-piperidinol; 4-Piperidinol, 1-benzyl-4-phenyl-; 1-Benzyl-4-phenyl-piperidin-4-ol; EINECS 264-512-8; 1-benzyl-4-hydroxy-4-phenylpiperidine; 1-benzyl-4-hydroxy-4-phenyl piperidine; BRN 0235839; CHEMBL230141; F1446-0078; NSC116051; AC1L3YAO; Oprea1_213406; Oprea1_173104; SCHEMBL1411499; AC1Q7B56; CTK5B9985; DTXSID60213290; MolPort-001-954-320; FCLMXEAPEVBCKQ-UHFFFAOYSA-N; ZINC320034; HMS1672E06; BCP13431; ANW-45516; BDBM50210409; STK081775; AKOS000541462
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21NO
|
|||
| Canonical SMILES |
C1CN(CCC1(C2=CC=CC=C2)O)CC3=CC=CC=C3
|
|||
| InChI |
1S/C18H21NO/c20-18(17-9-5-2-6-10-17)11-13-19(14-12-18)15-16-7-3-1-4-8-16/h1-10,20H,11-15H2
|
|||
| InChIKey |
FCLMXEAPEVBCKQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 63843-83-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nociceptin receptor (OPRL1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.